Roivant's Genevant/Arbutus settles Moderna LNP patent suit for $950M upfront, plus $1.3B contingent

Roivant Sciences Ltd.

Moderna to pay $950M non-contingent by July 8, 2026; additional $1.3B if Federal Circuit affirms rejection of Section 1498 defense.
Settlement includes judgment of no invalidity on four Genevant/Arbutus patents and a global non-exclusive license to LNP tech for infectious disease mRNA vaccines.
Roivant board authorizes $1B share repurchase program (includes prior $500M authorization), no expiration date.
Genevant/Arbutus continues litigation against Pfizer/BioNTech; Comirnaty sales represent ~2/3 of global COVID mRNA vaccine sales.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Roivant Sciences Ltd. entered into Settlement Agreement with Moderna, Inc. and ModernaTx, Inc. valued at $950.0 million noncontingent lump sum payment (effective 2026-03-03).

Action: entry
Agreement: settlement
Counterparty: Moderna, Inc. and ModernaTx, Inc.
Value: $950.0 million noncontingent lump sum payment
Effective: 2026-03-03

Exact text from the filing

On March 3, 2026 (the “Effective Date”), Genevant Sciences GmbH (“Genevant”), a subsidiary of Roivant Sciences Ltd. (the “Company” or “Roivant”), Arbutus Biopharma Corp. (together with Genevant, “Genevant/Arbutus”), and, solely for certain purposes, Genevant Sciences Ltd., and Moderna, Inc. and ModernaTx, Inc. (together, “Moderna”) entered into a settlement agreement (the “Settlement Agreement”)

View on SEC.gov

Browse all material agreements →

Roivant Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001140361-26-007548

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.